First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The company is making its entry into the Hyderabad market through its unique asset-light business model
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
The Group will continue to make proactive investments of its management resources in the life science business
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Subscribe To Our Newsletter & Stay Updated
